Examining the effect of chronic intranasal oxytocin administration on the neuroanatomy and behavior of three autism-related mouse models.
Administration, Intranasal
Animals
Autism Spectrum Disorder
/ drug therapy
Autistic Disorder
/ drug therapy
Disease Models, Animal
Fragile X Mental Retardation Protein
Humans
Mice
Microfilament Proteins
/ therapeutic use
Nerve Tissue Proteins
Neuroanatomy
Oxytocin
/ pharmacology
Random Allocation
Social Behavior
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
received:
14
02
2022
revised:
14
04
2022
accepted:
21
04
2022
pubmed:
5
5
2022
medline:
22
6
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
Although initially showing great potential, oxytocin treatment has encountered a translational hurdle in its promise of treating the social deficits of autism. Some debate surrounds the ability of oxytocin to successfully enter the brain, and therefore modify neuroanatomy. Moreover, given the heterogeneous nature of autism, treatment will only amerliorate symptoms in a subset of patients. Therefore, to determine whether oxytocin changes brain circuitry, and whether it does so variably, depending on genotype, we implemented a large randomized, blinded, placebo-controlled, preclinical study on chronic intranasal oxytocin treatment in three different mouse models related to autism with a focus on using neuroanatomical phenotypes to assess and subset treatment response. Intranasal oxytocin (0.6IU) was administered daily, for 28 days, starting at 5 weeks of age to the 16p11.2 deletion, Shank3 (exon 4-9) knockout, and Fmr1 knockout mouse models. Given the sensitivity of structural magnetic resonance imaging (MRI) to the neurological effects of interventions like drugs, along with many other advantages, the mice underwent in vivo longitudinal and high-resolution ex vivo imaging with MRI. The scans included three in vivo T1weighted, 90 um isotropic resolution scans and a T2-weighted, 3D fast spin echo with 40um isotropic resolution ex vivo scan to assess the changes in neuroanatomy using established automated image registration and deformation based morphometry approaches in response to oxytocin treatment. The behavior of the mice was assessed in multiple domains, including social behaviours and repetitive behaviours, among others. Treatment effect on the neuroanatomy did not reach significance, although the pattern of trending effects was promising. No significant effect of treatment was found on social behavior in any of the strains, although a significant effect of treatment was found in the Fmr1 mouse, with treatment normalizing a grooming deficit. No other treatment effect on behavior was observed that survived multiple comparisons correction. Overall, chronic treatment with oxytocin had limited effects on the three mouse models related to autism, and no promising pattern of response susceptibility emerged.
Identifiants
pubmed: 35508216
pii: S1053-8119(22)00367-6
doi: 10.1016/j.neuroimage.2022.119243
pii:
doi:
Substances chimiques
Fmr1 protein, mouse
0
Microfilament Proteins
0
Nerve Tissue Proteins
0
Shank3 protein, mouse
0
Fragile X Mental Retardation Protein
139135-51-6
Oxytocin
50-56-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119243Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interests.